Emerging glycolysis targeting and drug discovery from Chinese medicine in cancer therapy

Evidence-based Complementary and Alternative Medicine

Volumn 2012, Issue , 2012, Pages

  Wang, Zhiyu ^a   Wang, Neng ^a   Chen, Jianping ^a   Shen, Jiangang ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CAMPTOTHECIN; CHRYSIN; CURCUMIN; DEOXYGLUCOSE; ENOLASE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 1; HEXOKINASE ISOENZYME; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; LACTATE DEHYDROGENASE; OPHIORRHIZA TRICHOCARPON EXTRACT; PLANT EXTRACT; PROTEIN KINASE B; SALVIA MILTIORRHIZA EXTRACT; SODIUM GLUCOSE COTRANSPORTER 1; SPATHOLOBUS SUBERECTUS EXTRACT; TERPENOID; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER RESEARCH; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CHINESE MEDICINE; CURCUMA LONGA; DRUG DEVELOPMENT; DRUG EFFECT; ENDOCYTOSIS; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; GLYCOLYSIS; HUMAN; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; MEDICINAL PLANT; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPHIORRHIZA TRICHOCARPON; OROXYLUM; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SPATHOLOBUS SUBERECTUS; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84864957283     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2012/873175     Document Type: Review

References (127)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Ocana A., Pandiella A., Siu L. L., Tannock I. F., Preclinical development of molecular-targeted agents for cancer Nature Reviews Clinical Oncology 2011 8 4 200 209
3. Sharma P., Wagner K., Wolchok J. D., Allison J. P., Novel cancer immunotherapy agents with survival benefit: recent successes and next steps Nature Reviews Cancer 2011 11 11 805 812
4. Prat A., Baselga J., The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2 Nature Clinical Practice Oncology 2008 5 9 531 542
5. Ernst E., Complementary and alternative medicine (CAM) and cancer: the kind face of complementary medicine International Journal of Surgery 2009 7 6 499 500
6. Miller S., Stagl J., Wallerstedt D. B., Ryan M., Mansky P. J., Botanicals used in complementary and alternative medicine treatment of cancer: clinical science and future perspectives Expert Opinion on Investigational Drugs 2008 17 9 1353 1364
7. Carmady B., Smith C. A., Use of Chinese medicine by cancer patients: a review of surveys Chinese Medicine 2011 6 22
8. Hsiao W. L. W., Liu L., The role of traditional Chinese herbal medicines in cancer therapyfrom TCM theory to mechanistic insights Planta Medica 2010 76 11 1118 1131
9. Ouyang H., Wang P., Meng Z., Chen Z., Yu E., Jin H., Chang D. Z., Liao Z., Cohen L., Liu L., Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine Pancreas 2011 40 1 120 125
10. Wang S., Penchala S., Prabhu S., Wang J., Huang Y., Molecular basis of traditional chinese medicine in cancer chemoprevention Current Drug Discovery Technologies 2010 7 1 67 75
11. Parekh H. S., Liu G., Wei M. Q., A new dawn for the use of traditional Chinese medicine in cancer therapy Molecular Cancer 2009 8 21
12. Craig W. J., Phytochemicals: guardians of our health Journal of the American Dietetic Association 1997 97 10 S199 S204
13. Craig W. J., Health-promoting properties of common herbs The American Journal of Clinical Nutrition 1999 70 3 491S 499S (Pubitemid 29407127)
14. Newman D. J., Cragg G. M., Snader K. M., Natural products as sources of new drugs over the period 19812002 Journal of Natural Products 2003 66 7 1022 1037 (Pubitemid 36909859)
15. Efferth T., Li P. C. H., Konkimalla V. S. B., Kaina B., From traditional Chinese medicine to rational cancer therapy Trends in Molecular Medicine 2007 13 8 353 361 (Pubitemid 47126989)
16. Cheng C. W., Fan W., Ko S. G., Song L., Bian Z. X., Evidence-based management of herb-drug interaction in cancer chemotherapy Explore 2010 6 5 324 329
17. Wang S., Penchala S., Prabhu S., Wang J., Huang Y., Molecular basis of traditional chinese medicine in cancer chemoprevention Current Drug Discovery Technologies 2010 7 1 67 75
18. Aggarwal B. B., Ichikawa H., Garodia P., Weerasinghe P., Sethi G., Bhatt I. D., Pandey M. K., Shishodia S., Nair M. G., From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer Expert Opinion on Therapeutic Targets 2006 10 1 87 118 (Pubitemid 43263269)
19. Yim K. L., Cunningham D., Targeted drug therapies and cancer Recent Results in Cancer Research 2011 185 159 171
20. Takeuchi K., Ito F., Receptor tyrosine kinases and targeted cancer therapeutics Biologilca and Pharmaceutical Bulletin 2011 34 12 1774 1780
21. Allgayer H., Fulda S., An introduction to molecular targeted therapy of cancer Advances in Medical Sciences 2008 53 2 130 138
22. Nadal E., Olavarria E., Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies International Journal of Clinical Practice 2004 58 5 511 516 (Pubitemid 38786574)
23. Nahta R., Esteva F. J., HER-2-targeted therapy: lessons learned and future directions Clinical Cancer Research 2003 9 14 5078 5084 (Pubitemid 37413555)
24. Vlacich G., Coffey R., Resistance to EGFR-targeted therapy: a family affair Cancer Cell 2011 20 4 423 425
25. Rini B. I., Atkins M. B., Resistance to targeted therapy in renal-cell carcinoma The Lancet Oncology 2009 10 10 992 1000
26. Vander Heiden M. G., Targeting cancer metabolism: a therapeutic window opens Nature Reviews Drug Discovery 2011 10 9 671 684
27. Ferreira L. M. R., Cancer metabolism: the Warburg effect today Experimental and Molecular Pathology 2010 89 3 372 380
28. Najafov A., Alessi D. R., Uncoupling the warburg effect from cancer Proceedings of the National Academy of Sciences of the United States of America 2010 107 45 19135 19136
29. Liu X., Wang X., Zhang J., Lam E. K. Y., Shin V. Y., Cheng A. S. L., Yu J., Chan F. K. L., Sung J. J. Y., Jin H. C., Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis Oncogene 2010 29 3 442 450
30. Lu H., Forbes R. A., Verma A., Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis Journal of Biological Chemistry 2002 277 26 23111 23115 (Pubitemid 34952134)
31. Pelicano H., Martin D. S., Xu R. H., Huang P., Glycolysis inhibition for anticancer treatment Oncogene 2006 25 34 4633 4646 (Pubitemid 44187614)
32. Porporato P. E., Dhup S., Dadhich R. K., Copetti T., Sonveaux P., Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review Frontiers in Pharmacology 2011 2 49
33. Warburg O., On respiratory impairment in cancer cells Science 1956 124 3215 269 270
34. Ferreira L. M. R., Cancer metabolism: the Warburg effect today Experimental and Molecular Pathology 2010 89 3 372 380
35. Hsu P. P., Sabatini D. M., Cancer cell metabolism: Warburg and beyond Cell 2008 134 5 703 707
36. Garber K., Energy boost: the Warburg effect returns in a new theory of cancer Journal of the National Cancer Institute 2004 96 24 1805 1806 (Pubitemid 40081310)
37. Bayley J. P., Devilee P., The Warburg effect in 2012 Current Opinion in Oncology 2012 24 1 62 67
38. Stubbs M., Griffiths J. R., The altered metabolism of tumors: HIF-1 and its role in the Warburg effect Advances in Enzyme Regulation 2010 50 1 44 55
39. Vander Heiden M. G., Cantley L. C., Thompson C. B., Understanding the Warburg effect: the metabolic requirements of cell proliferation Science 2009 324 5930 1029 1033
40. Shanmugam M., McBrayer S. K., Rosen S. T., Targeting the Warburg effect in hematological malignancies: from PET to therapy Current Opinion in Oncology 2009 21 6 531 536
41. Chen Z., Lu W., Garcia-Prieto C., Huang P., The Warburg effect and its cancer therapeutic implications Journal of Bioenergetics and Biomembranes 2007 39 3 267 274 (Pubitemid 47619379)
42. Scatena R., Bottoni P., Pontoglio A., Giardina B., Revisiting the Warburg effect in cancer cells with proteomics. The emergence of new approaches to diagnosis, prognosis and therapy Proteomics Clinical Applications 2010 4 2 143 158
43. Gatenby R. A., Gillies R. J., Glycolysis in cancer: a potential target for therapy International Journal of Biochemistry Cell Biology 2007 39 7-8 1358 1366 (Pubitemid 47031043)
44. Lunt S. Y., Vander Heiden M. G., Aerobic glycolysis: meeting the metabolic requirements of cell proliferation Annual Review of Cell and Developmental Biology 2011 27 441 464
45. Podar K., Anderson K. C., A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways Cell Cycle 2010 9 9 1722 1728
46. Yoo Y. G., Hayashi M., Christensen J., Huang L. E., An essential role of the HIF-1 -c-Myc axis in malignant progression Annals of the New York Academy of Sciences 2009 1177 198 204
47. Brown R. S., Goodman T. M., Zasadny K. R., Greenson J. K., Wahl R. L., Expression of hexokinase II and Glut-1 in untreated human breast cancer Nuclear Medicine and Biology 2002 29 4 443 453 (Pubitemid 34597116)
48. Kolev Y., Uetake H., Takagi Y., Sugihara K., Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1 ) pathway, angiogenic factors production and poor prognosis Annals of Surgical Oncology 2008 15 8 2336 2344
49. Higashimura Y., Nakajima Y., Yamaji R., Harada N., Shibasaki F., Nakano Y., Inui H., Up-regulation of glyceraldehyde-3-phosphate dehydrogenase gene expression by HIF-1 activity depending on Sp1 in hypoxic breast cancer cells Archives of Biochemistry and Biophysics 2011 509 1 1 8
50. Xie H., Valera V. A., Merino M. J., Amato A. M., Signoretti S., Linehan W. M., Sukhatme V. P., Seth P., LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer Molecular Cancer Therapeutics 2009 8 3 626 635
51. Shi H. S., Li D., Zhang J., Wang Y. S., Yang L., Zhang H. L., Wang X. H., Mu B., Wang W., Ma Y., Guo F. C., Wei Y. Q., Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice Cancer Science 2010 101 6 1447 1453
52. Zhou M., Zhao Y., Ding Y., Liu H., Liu Z., Fodstad O., Riker A. I., Kamarajugadda S., Lu J., Owen L. B., Ledoux S. P., Tan M., Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol Molecular Cancer 2010 9 33
53. Ogino T., Yamadera T., Nonaka T., Imajoh-Ohmi S., Mizumoto K., Enolase, a cellular glycolytic enzyme, is required for efficient transcription of Sendai virus genome Biochemical and Biophysical Research Communications 2001 285 2 447 455 (Pubitemid 32918091)
54. Pastorino J. G., Hoek J. B., Hexokinase II: the integration of energy metabolism and control of apoptosis Current Medicinal Chemistry 2003 10 16 1535 1551 (Pubitemid 36896555)
55. Dobashi Y., Watanabe H., Matsubara M., Yanagawa T., Raz A., Shimamiya T., Ooi A., Autocrine motility factor/glucose-6-phosphate isomerase is a possible predictor of metastasis in bone and soft tissue tumours Journal of Pathology 2006 208 1 44 53 (Pubitemid 43025702)
56. Semenza G. L., HIF-1: upstream and downstream of cancer metabolism Current Opinion in Genetics Development 2010 20 1 51 56
57. Lauzier M. C., Michaud M. D., Déry M. A. C., Richard D. E., HIF-1 activation during tumor progression: implications and consequences Bulletin du Cancer 2006 93 4 349 356 (Pubitemid 43742483)
58. Monti E., Gariboldi M. B., HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention Current Molecular Pharmacology 2011 4 1 62 77
59. Adams J. M., Difazio L. T., Rolandelli R. H., Lujn J. J., Hask G., Cska B., Selmeczy Z., Németh Z. H., HIF-1: a key mediator in hypoxia (Review) Acta Physiologica Hungarica 2009 96 1 19 28
60. Semenza G. L., Hypoxia-inducible factor 1 (HIF-1) pathway Science's STKE 2007 407 cm8
61. Koh M. Y., Spivak-Kroizman T. R., Powis G., HIF-1 regulation: not so easy come, easy go Trends in Biochemical Sciences 2008 33 11 526 534
62. Ziello J. E., Jovin I. S., Huang Y., Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia Yale Journal of Biology and Medicine 2007 80 2 51 60
63. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
64. Semenza G. L., HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery Current Pharmaceutical Design 2009 15 33 3839 3843
65. Choi E. J., Kim G. H., Apigenin induces apoptosis through a mitochondria/caspase-pathway in human breast cancer MDA-MB-453 cells Journal of Clinical Biochemistry and Nutrition 2009 44 3 260 265
66. Li Z. D., Hu X. W., Wang Y. T., Fang J., Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1 FEBS Letters 2009 583 12 1999 2003
67. Shukla S., Gupta S., Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft Molecular Cancer Therapeutics 2006 5 4 843 852 (Pubitemid 43724583)
68. Lu H. F., Chie Y. U. J., Yang M. S., Lee C. S., Fu J. J., Yang J. S., Tan T. W., Wu S. H., Ma Y. I. S., Ip S. W., Chung J. G., Apigenin induces caspase-dependent apoptosis in human lung cancer A549 cells through Bax- and Bcl-2-triggered mitochondrial pathway International Journal of Oncology 2010 36 6 1477 1484
69. Fang J., Zhou Q., Liu L. Z., Xia C., Hu X., Shi X., Jiang B. H., Apigenin inhibits tumor angiogenesis through decreasing HIF-1 and VEGF expression Carcinogenesis 2007 28 4 858 864 (Pubitemid 46523341)
70. Liu L. Z., Fang J., Zhou Q., Hu X., Shi X., Jiang B. H., Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer Molecular Pharmacology 2005 68 3 635 643 (Pubitemid 41206017)
71. Shukla S., Gupta S., Apigenin-induced cell cycle arrest is mediated by modulation of MAPK, PI3K-Akt, and loss of cyclin D1 associated retinoblastoma dephosphorylation in human prostate cancer cells Cell Cycle 2007 6 9 1102 1114 (Pubitemid 46708584)
72. Kaur P., Shukla S., Gupta S., Plant flavonoid apigenin inactivates Akt to trigger apoptosis in human prostate cancer: an in vitro and in vivo study Carcinogenesis 2008 29 11 2210 2217
73. Mirzoeva S., Kim N. D., Chiu K., Franzen C. A., Bergan R. C., Pelling J. C., Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells Molecular Carcinogenesis 2008 47 9 686 700
74. Osada M., Imaoka S., Funae Y., Apigenin suppresses the expression of VEGF, an important factor for angiogenesis, in endothelial cells via degradation of HIF-1 protein FEBS Letters 2004 575 1-3 59 63 (Pubitemid 39237681)
75. Samarghandian S., Afshari J. T., Davoodi S., Chrysin reduces proliferation and induces apoptosis in the human prostate cancer cell line pc-3 Clinics 2011 66 6 1073 1079
76. Phan T., Yu X. M., Kunnimalaiyaan M., Chen H., Antiproliferative effect of chrysin on anaplastic thyroid cancer Journal of Surgical Research 2011 170 1 84 88
77. Khoo B. Y., Chua S. L., Balaram P., Apoptotic effects of chrysin in human cancer cell lines International Journal of Molecular Sciences 2010 11 5 2188 2199
78. Fu B., Xue J., Li Z., Shi X., Jiang B. H., Fang J., Chrysin inhibits expression of hypoxia-inducible factor 1- through reducing hypoxia-inducible factor-1 stability and inhibiting its protein synthesis Molecular Cancer Therapeutics 2007 6 1 220 226 (Pubitemid 46206685)
79. Singh B. N., Shankar S., Srivastava R. K., Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications Pharmacology 2011 82 12 1807 1821
80. Nagle D. G., Ferreira D., Zhou Y. D., Epigallocatechin-3-gallate (EGCG): chemical and biomedical perspectives Phytochemistry 2006 67 17 1849 1855 (Pubitemid 44291411)
81. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H., Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate Cancer Research 2006 66 5 2500 2505
82. Tachibana H., Molecular basis for cancer chemoprevention by green tea polyphenol EGCG Forum of Nutrition 2009 61 156 169
83. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., Le A. D., Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells Molecular Cancer Therapeutics 2006 5 5 1227 1238 (Pubitemid 43881315)
84. Zhou H., Beevers C. S., Huang S., The targets of curcumin Current Drug Targets 2011 12 3 332 347
85. Hossain D. M., Bhattacharyya S., Das T., Sa G., Curcumin: the multi-targeted therapy for cancer regression Frontiers in Biosciences 2012 4 335 355
86. Bae M. K., Kim S. H., Jeong J. W., Lee Y. M., Kim H. S., Kim S. R., Yun I., Bae S. K., Kim K. W., Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1 Oncology Reports 2006 15 6 1557 1562
87. Strfer M., Jelkmann W., Depping R., Curcumin decreases survival of Hep3B liver and MCF-7 Breast Cancer Cellsthe role of HIF Strahlentherapie und Onkologie 2011 187 7 393 400
88. Klausmeyer P., McCloud T. C., Melillo G., Scudiero D. A., Cardellina J. H., Shoemaker R. H., Identification of a new natural camptothecin analogue in targeted screening for HIF-1 inhibitors Planta Medica 2007 73 1 49 52 (Pubitemid 46909851)
89. Nguyen T. D., Jin X., Lee J. H., Lee D., Hong Y. S., Lee K., Young H. K., Jung J. L., Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1 Journal of Natural Products 2007 70 7 1093 1097 (Pubitemid 47287438)
90. Kawai S., Mukai T., Mori S., Mikami B., Murata K., Hypothesis: structures, evolution, and ancestor of glucose kinases in the hexokinase family Journal of Bioscience and Bioengineering 2005 99 4 320 330 (Pubitemid 40740581)
91. Fan Y., Zong W. X., Hacking hexokinase halts tumor growth Cancer Biology and Therapy 2008 7 7 1136 1138
92. Rempel A., Mathupala S. P., Griffin C. A., Hawkins A. L., Pedersen P. L., Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase Cancer Research 1996 56 11 2468 2471 (Pubitemid 26170674)
93. Pastorino J. G., Hoek J. B., Regulation of hexokinase binding to VDAC Journal of Bioenergetics and Biomembranes 2008 40 3 171 182
94. Galluzzi L., Kepp O., Tajeddine N., Kroemer G., Disruption of the hexokinase-VDAC complex for tumor therapy Oncogene 2008 27 34 4633 4635
95. Aft R. L., Zhang F. W., Gius D., Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death British Journal of Cancer 2002 87 7 805 812 (Pubitemid 35178760)
96. Dell'Antone P., Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent Medicinal Chemistry 2009 5 6 491 496
97. Yang H. L., Zhang H. X., Li L. H., Wang Y., Lu S. L., Sun S. M., Zhang W. W., Effect of bencao xiaoke pill on carbohydrate metabolism enzyme activity in type 2 diabetic rats Lishizhen Medicine and Materia Medica Research 2009 20 7 1615 1616
98. Ezekwudo D. E., Wang R. C., Elegbede J. A., Methyl jasmonate induced apoptosis in human prostate carcinoma cells via 5-lipoxygenase dependent pathway Journal of Experimental Therapeutics Oncology 2007 6 4 267 277 (Pubitemid 350104816)
99. Milrot E., Jackman A., Kniazhanski T., Gonen P., Flescher E., Sherman L., Methyl jasmonate reduces the survival of cervical cancer cells and downregulates HPV E6 and E7, and surviving Cancer Letters 2012 319 1 31 38
100. Xiao X. Y., Jiang G. S., Wang L., Lv L., Zeng F. Q., Predominant enhancement of apoptosis induced by methyl jasmonate in bladder cancer cells: therapeutic effect of the antp-conjugated Smac peptide Anti-Cancer Drugs 2011 22 9 853 863
101. Goldin N., Arzoine L., Heyfets A., Israelson A., Zaslavsky Z., Bravman T., Bronner V., Notcovich A., Shoshan-Barmatz V., Flescher E., Methyl jasmonate binds to and detaches mitochondria-bound hexokinase Oncogene 2008 27 34 4636 4643
102. Augoff K., Grabowski K., Significance of lactate dehydrogenase measurements in diagnosis of malignancies Polski Merkuriusz Lekarski 2004 17 102 644 647 (Pubitemid 40091956)
103. Kanno T., Sudo K., Takeuchi I., Hereditary deficiency of lactate dehydrogenase M-subunit Clinica Chimica Acta 1980 108 2 267 276 (Pubitemid 11243032)
104. Koukourakis M. I., Giatromanolaki A., Winter S., Leek R., Sivridis E., Harris A. L., Lactate dehydrogenase 5 expression in squamous cell head and neck cancer relates to prognosis following radical or postoperative radiotherapy Oncology 2009 77 5 285 292
105. Le A., Cooper C. R., Gouw A. M., Dinavahi R., Maitra A., Deck L. M., Royer R. E., Vander Jagt D. L., Semenza G. L., Dang C. V., Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proceedings of the National Academy of Sciences of the United States of America 2010 107 5 2037 2042
106. Wang Z. Y., Loo T. Y., Shen J. G., Wang N., Wang D. M., Yang D. P., Mo S. L., Guan X. Y., Chen J. P., LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis Breast Cancer Research and Treatment 2012 131 3 791 800
107. Pang X., Wu Y., Wu Y., Lu B., Chen J., Wang J., Yi Z., Qu W., Liu M., (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis Molecular Cancer Therapeutics 2011 10 5 795 805
108. Sikora M. J., Bauer J. A., Verhaegen M., Belbin T. J., Prystowsky M. B., Taylor J. C., Brenner J. C., Wang S., Soengas M. S., Bradford C. R., Carey T. E., Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol Cancer Biology Therapy 2008 7 5 767 776
109. Vander Jagt D. L., Deck L. M., Royer R. E., Gossypol: prototype of inhibitors targeted to dinucleotide folds Current Medicinal Chemistry 2000 7 4 479 498 (Pubitemid 30396437)
110. Conners R., Schambach F., Read J., Cameron A., Sessions R. B., Vivas L., Easton A., Croft S. L., Brady R. L., Mapping the binding site for gossypol-like inhibitors of Plasmodium falciparum lactate dehydrogenase Molecular and Biochemical Parasitology 2005 142 2 137 148 (Pubitemid 40835905)
111. Javed M. H., Khan M. A., Effect of amino acids on inhibition of lactate dehydogenase-X by gossypol Experimental and Molecular Medicine 1999 31 1 25 29 (Pubitemid 29167182)
112. Kovaci P., Mechanism of drug and toxic actions of gossypol: focus on reactive oxygen species and electron transfer Current Medicinal Chemistry 2003 10 24 2711 2718 (Pubitemid 37456041)
113. Manerba M., Vettraino M., Fiume L., di Stefano G., Sartini A., Giacomini E., Buonfiglio R., Roberti M., Recanatini M., Galloflavin (CAS 568-80-9): a novel inhibitor of lactate dehydrogenase ChemMedChem 2012 7 2 311 317
114. Le A., Cooper C. R., Gouw A. M., Dinavahi R., Maitra A., Deck L. M., Royer R. E., Vander Jagt D. L., Semenza G. L., Dang C. V., Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression Proceedings of the National Academy of Sciences of the United States of America 2010 107 5 2037 2042
115. Brophy S., Sheehan K. M., McNamara D. A., Deasy J., Bouchier-Hayes D. J., Kay E. W., GLUT-1 expression and response to chemoradiotherapy in rectal cancer International Journal of Cancer 2009 125 12 2778 2782
116. Rastogi S., Banerjee S., Chellappan S., Simon G. R., Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines Cancer Letters 2007 257 2 244 251 (Pubitemid 47538826)
117. Melstrom L. G., Salabat M. R., Ding X. Z., Milam B. M., Strouch M., Pelling J. C., Bentrem D. J., Apigenin inhibits the GLUT-1 glucose transporter and the phosphoinositide 3-kinase/akt pathway in human pancreatic cancer cells Pancreas 2008 37 4 426 431
118. Vera J. C., Reyes A. M., Crcamo J. G., Velsquez F. V., Rivas C. I., Zhang R. H., Strobel P., Iribarren R., Scher H. I., Siebe J. C., Golde D. W., Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1 Journal of Biological Chemistry 1996 271 15 8719 8724 (Pubitemid 26123289)
119. Tarze A., Deniaud A., le Bras M., Maillier E., Molle D., Larochette N., Zamzami N., Jan G., Kroemer G., Brenner C., GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization Oncogene 2007 26 18 2606 2620 (Pubitemid 46632015)
120. Gregus Z., Németi B., The glycolytic enzyme glyceraldehyde-3- phosphate dehydrogenase works as an arsenate reductase in human red blood cells and rat liver cytosol Toxicological Sciences 2005 85 2 859 869 (Pubitemid 40846860)
121. Luo Z., Zang M., Guo W., AMPK as a metabolic tumor suppressor: control of metabolism and cell growth Future Oncology 2010 6 3 457 470
122. Pan W., Yang H., Cao C., Song X., Wallin B., Kivlin R., Lu S., Hu G., Di W., Wan Y., AMPK mediates curcumin-induced cell death in CaOV3 ovarian cancer cells Oncology Reports 2008 20 6 1553 1559
123. Kim H. J., Kim S. K., Kim B. S., Lee S. H., Park Y. S., Park B. K., Kim S. J., Kim J., Choi C., Kim J. S., Cho S. D., Jung J. W., Roh K. H., Kang K. S., Jung J. Y., Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway Journal of Agricultural and Food Chemistry 2010 58 15 8643 8650
124. Zhao Y., Liu H., Liu Z., Ding Y., LeDoux S. P., Wilson G. L., Voellmy R., Lin Y., Lin W., Nahta R., Liu B., Fodstad O., Chen J., Wu Y., Price J. E., Tan M., Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism Cancer Research 2011 71 13 4585 4597
125. Suh D. H., Kim M. K., No J. H., Chung H. H., Song Y. S., Metabolic approaches to overcoming chemoresistance in ovarian cancer Annals of the New York Academy of Sciences 2011 1229 1 53 60
126. Zhou M., Zhao Y., Ding Y., Liu H., Liu Z., Fodstad O., Riker A. I., Kamarajugadda S., Lu J., Owen L. B., Ledoux S. P., Tan M., Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol Molecular Cancer 2010 9 33
127. Pitroda S. P., Wakim B. T., Sood R. F., Beveridge M. G., Beckett M. A., MacDermed D. M., Weichselbaum R. R., Khodarev N. N., STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect BMC Medicine 2009 7 68